Reducing Chronic Inflammation in Atherosclerosis with an Old Drug

Inflammation plays a crucial role in atherosclerosis progression. Recently, the COLCOT study has shown the benefits of colchicine in cardiovascular events. 

Colchicina para reducir la inflamación crónica de la aterosclerosis

This good old drug has an inflammatory effect which attenuates the NLRP3 cascade. This explains its effect on uric acid crystals in gout, which might be the same on atherosclerosis cholesterol crystals. 

This study called LoDoCo2 and published in Circulation, studied the potential anti-inflammatory effect of colchicine in patients with chronic coronary artery disease comparing lab exams 30 days before and after receiving the drug. 

It included 174 patients that had suffered acute coronary syndrome within the prior 6 months. 

A blood sample was obtained from all patients to quantify 184 proteins associated with inflammation at baseline, and another one after 30 days of receiving colchicine 0.5 mg/day plus all the standard medical treatment. 


Read also: AHA 2019 | COLCOT: Colchicine and the Return of the Anti-Inflammatory Theory.


At 30 days, there was a significant reduction of 37 proteins associated to inflammation (p<0.05). Attenuation of the NLRP3 inflammatory cascade was supported by a reduction of interleukin 18, IL-1 receptor antagonist, and IL-6. 

Other pro-inflammatory proteins not directly associated with the NLRP3 pathway also saw a reduction, especially those related to neutrophil degranulation. 

Conclusion

This study showed a significant reduction of multiple proteins related with inflammation after 30 days of treatment with low doses of colchicine in patients with chronic CAD. The anti-inflammatory effect of this drug exceeds the NLRP3 cascade effect, which suggests an important role in neutrophil inhibition. 

Original Title: Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy.

Reference: Tjerk S.J. Opstal et al. Circulation. 2020 Nov 17;142(20):1996-1998. doi: 10.1161/CIRCULATIONAHA.120.050560.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...